Table 1. Clinical characteristics of included trials.
| Trial | Design | Time | Region | Primary | Treatment | Sample | Median follow-up |
|---|---|---|---|---|---|---|---|
| Range | Endpoint | Size | (months) | ||||
| NEJ002/2010[4–5] | III | 2006–2009 | Multicenter | PFS | F-TKIs | 114 | >17 |
| CT | 114 | ||||||
| WJTOG3405/2010[6–7] | III | 2006–2009 | Japan | PFS | F-TKIs | 86 | 34 |
| CT | 86 | ||||||
| EURTAC/2012[8] | III | 2007–2011 | Multicenter | PFS | F-TKIs | 86 | 18.9 |
| CT | 87 | 14.4 | |||||
| OPTIMAL/2011[9–10] | III | 2011–2014 | China | PFS | F-TKIs | 82 | 25.9 |
| CT | 72 | ||||||
| LUX-Lung7/2016[11–12] | II | 2011–2013 | Multicenter | PFS | S-TKIs | 160 | 42.6 |
| F-TKIs | 159 | ||||||
| ARCHER1050/2017[13–14] | III | 2013–2015 | Asian | PFS | S-TKIs | 227 | 22.1 |
| F-TKIs | 225 | ||||||
| FLAURA/2017[15] | III | 2014–2016 | Multicenter | PFS | Osimertinib | 279 | 15 |
| F-TKIs | 277 | 9.7 | |||||
| FASTACT-2/2013[16] | II | 2009–2010 | Asian | PFS | F-TKIs+CT | 49 | 27.6 |
| CT | 48 | ||||||
| Yu/2014[17] | II | 2010–2012 | China | ORR | F-TKIs+CT | 14 | NR |
| CT | 18 | ||||||
| Cheng/2016[18] | II | 2012–2013 | Asian | PFS | F-TKIs+CT | 126 | NR |
| F-TKIs | 65 | ||||||
| NEJ009/2018[19] | III | 2011–2014 | Japan | PFS | F-TKIs+CT | 172 | NR |
| F-TKIs | 170 | ||||||
| JO25567/2014[20–21] | II | 2011–2012 | Japan | PFS | F-TKIs+Bev | 75 | 25.9 |
| F-TKIs | 77 | 27 | |||||
| NEJ026/2018[22] | III | NR | Japan | PFS | F-TKIs+Bev | 112 | 12.4 |
| F-TKIs | 112 | ||||||
| CONVINCE/2017[25] | III | 2013–2014 | China | PFS | F-TKIs | 148 | 18 |
| CT | 137 | 15.7 | |||||
| IPASS/2009[35–36] | III | 2005–2008 | Asian | PFS | F-TKIs | 132 | 17 |
| CT | 129 | ||||||
| TORCH/2012[37] | III | 2006–2009 | Italy, Canada | OS | F-TKIs | 19 | 24.3 |
| CT | 20 | ||||||
| Chen/2012[38] | II | 2007–2008 | China | PFS | F-TKIs | 9 | NR |
| CT | 15 | ||||||
| ENSURE/2015[39] | III | 2011–2012 | Asian | PFS | F-TKIs | 110 | 28.9 |
| CT | 107 | 27.1 | |||||
| Han/2012[40] | III | 2005–2007 | Korea | OS | F-TKIs | 26 | 35 |
| CT | 16 | ||||||
| LUX-Lung3/2013[41–42] | III | 2009–2011 | Multicenter | PFS | S-TKIs | 230 | 41 |
| CT | 115 | ||||||
| LUX-Lung6/2014[42–43] | III | 2010–2011 | Asian | PFS | S-TKIs | 242 | 33 |
| CT | 122 | ||||||
| Hirsch/2011[44] | II | 2007–2008 | Multicenter | PFS | F-TKIs+CT | 6 | NR |
| F-TKIs | 9 | ||||||
| CALGB30406/2012[45] | II | 2005–2009 | United States | PFS | F-TKIs+CT | 33 | 38 |
| F-TKIs | 33 | ||||||
| TRIBUTE/2005[46] | III | 2001–2002 | United States | OS | F-TKIs+CT | 93 | NR |
| CT | 74 | NR | |||||
| Leighl/2017[47] | II | NR | Multicenter | PFS | F-TKIs+Lin | 44 | NR |
| F-TKIs | 44 |
Abbreviations: PFS, progression-free survival; OS, overall survival; ORR, overall response rate; NR, not reported; TKIs, tyrosine kinase inhibitor; F, first-generation; S, second-generation; Bev, bevacizumab; CT, chemotherapy; Lin, Linsitinib.